Drug developers said on Monday that after two trials were postponed due to problems with the expansion of the production process, Novax has begun a large-scale late-stage study of its experimental Covid-19 vaccine in the United States.
The company said it will recruit up to 30,000 volunteers in approximately 115 locations in the United States and Mexico, with two-thirds receiving injections 21 days apart and the rest receiving placebo treatment.
In the global COVID-19 vaccine competition, Novavax lags behind other drugmakers, and Pfizer and Moderna’s vaccines have been approved for emergency use in the United States.
But experts say that to end the global pandemic of more than 1
Novavax has signed supply agreements with a number of countries/regions and plans to provide 60 million doses to the UK, which is undergoing late-stage research. Provisional data for this trial is expected in the first quarter of 2021.
After receiving a $1.6 billion award for the development and testing of its potential vaccine, the company is also preparing to deliver 100 million doses to the United States in January.
Novavax is also conducting fully registered Phase 2b clinical trials in South Africa and Phase 1/2 clinical trials in the United States and Australia. The efficacy data of the trial will be available early next year.